Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHD

Bitget2026/09/21 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Alkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD; results have already been presented.
The investigational orexin 2 receptor agonist showed clinically meaningful symptom improvement versus baseline, supporting further development in ADHD.
Safety profile was generally tolerable in healthy volunteers and adult patients; no serious treatment-emergent adverse events were reported.
A Phase 2 trial is enrolling, with data expected in 2027; the first participant was dosed in September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202609210700BIZWIRE_USPR_____20260921_BW142041) on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHD

You may also like

Crypto prices